Andrew Berens
Stock Analyst at Leerink Partners
(2.38)
# 2,592
Out of 5,072 analysts
101
Total ratings
50.56%
Success rate
-3.61%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Berens
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AGIO Agios Pharmaceuticals | Upgrades: Outperform | $40 → $34 | $29.04 | +17.08% | 12 | Nov 20, 2025 | |
| NUVL Nuvalent | Maintains: Outperform | $140 → $149 | $109.15 | +36.51% | 3 | Nov 17, 2025 | |
| COGT Cogent Biosciences | Maintains: Outperform | $18 → $50 | $40.39 | +23.79% | 6 | Nov 10, 2025 | |
| IMRX Immuneering | Initiates: Outperform | $15 | $7.51 | +99.73% | 1 | Oct 31, 2025 | |
| MRUS Merus | Downgrades: Market Perform | $95 → $97 | $96.09 | +0.95% | 6 | Oct 6, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Initiates: Outperform | $25 | $12.18 | +105.25% | 1 | Sep 17, 2025 | |
| CELC Celcuity | Maintains: Outperform | $28 → $60 | $100.35 | -40.21% | 2 | Jul 28, 2025 | |
| ARVN Arvinas | Downgrades: Market Perform | $10 → $9 | $12.42 | -27.54% | 6 | Jun 2, 2025 | |
| CMPX Compass Therapeutics | Upgrades: Outperform | $4 → $6 | $5.39 | +11.32% | 3 | Apr 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Market Perform | $880 → $762 | $784.61 | -2.88% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $2.88 | +1,047.83% | 1 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $10 → $25 | $27.33 | -8.53% | 10 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $74 → $96 | $127.51 | -24.71% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $78 | $105.65 | -26.17% | 12 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $28 | $17.20 | +62.79% | 3 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $79 | $93.32 | -15.35% | 12 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $27 | $1.44 | +1,775.00% | 7 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $25 | $11.74 | +112.95% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $6.38 | +526.96% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $67 | $2.68 | +2,400.00% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $20 | $15.99 | +25.08% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $10.76 | +132.34% | 1 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $8 | $12.14 | -34.10% | 7 | Jul 14, 2017 |
Agios Pharmaceuticals
Nov 20, 2025
Upgrades: Outperform
Price Target: $40 → $34
Current: $29.04
Upside: +17.08%
Nuvalent
Nov 17, 2025
Maintains: Outperform
Price Target: $140 → $149
Current: $109.15
Upside: +36.51%
Cogent Biosciences
Nov 10, 2025
Maintains: Outperform
Price Target: $18 → $50
Current: $40.39
Upside: +23.79%
Immuneering
Oct 31, 2025
Initiates: Outperform
Price Target: $15
Current: $7.51
Upside: +99.73%
Merus
Oct 6, 2025
Downgrades: Market Perform
Price Target: $95 → $97
Current: $96.09
Upside: +0.95%
BridgeBio Oncology Therapeutics
Sep 17, 2025
Initiates: Outperform
Price Target: $25
Current: $12.18
Upside: +105.25%
Celcuity
Jul 28, 2025
Maintains: Outperform
Price Target: $28 → $60
Current: $100.35
Upside: -40.21%
Arvinas
Jun 2, 2025
Downgrades: Market Perform
Price Target: $10 → $9
Current: $12.42
Upside: -27.54%
Compass Therapeutics
Apr 2, 2025
Upgrades: Outperform
Price Target: $4 → $6
Current: $5.39
Upside: +11.32%
Regeneron Pharmaceuticals
Jan 28, 2025
Maintains: Market Perform
Price Target: $880 → $762
Current: $784.61
Upside: -2.88%
Dec 5, 2024
Initiates: Outperform
Price Target: $33
Current: $2.88
Upside: +1,047.83%
Nov 7, 2024
Upgrades: Outperform
Price Target: $10 → $25
Current: $27.33
Upside: -8.53%
Oct 21, 2024
Upgrades: Outperform
Price Target: $74 → $96
Current: $127.51
Upside: -24.71%
Dec 13, 2023
Upgrades: Outperform
Price Target: $78
Current: $105.65
Upside: -26.17%
Dec 13, 2022
Maintains: Outperform
Price Target: $37 → $28
Current: $17.20
Upside: +62.79%
Nov 14, 2022
Maintains: Outperform
Price Target: $78 → $79
Current: $93.32
Upside: -15.35%
Nov 10, 2022
Maintains: Outperform
Price Target: $42 → $27
Current: $1.44
Upside: +1,775.00%
May 13, 2022
Maintains: Outperform
Price Target: $36 → $25
Current: $11.74
Upside: +112.95%
Nov 23, 2021
Initiates: Outperform
Price Target: $40
Current: $6.38
Upside: +526.96%
Oct 14, 2021
Initiates: Outperform
Price Target: $67
Current: $2.68
Upside: +2,400.00%
Oct 14, 2021
Initiates: Market Perform
Price Target: $20
Current: $15.99
Upside: +25.08%
Sep 20, 2021
Initiates: Outperform
Price Target: $25
Current: $10.76
Upside: +132.34%
Jul 14, 2017
Maintains: Equal-Weight
Price Target: $16 → $8
Current: $12.14
Upside: -34.10%